Cyclooxygenase-2 Inhibitors, Nonsteroidal Anti-inflammatory Drugs, and Cardiovascular Risk

Cardiology Clinics

Volumn 26, Issue 4, 2008, Pages 589-601

  Vardeny, Orly ^a   Solomon, Scott D ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cardiovascular disease; Cyclooxygenase 2 inhibitors; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETORICOXIB; IBUPROFEN; INDOMETACIN; LUMIRACOXIB; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PROSTACYCLIN; PROSTAGLANDIN; PROTON PUMP INHIBITOR; ROFECOXIB; THROMBOXANE; TRAMADOL; VALDECOXIB;

ANALGESIA; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLON POLYP; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HAZARD RATIO; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; JUVENILE RHEUMATOID ARTHRITIS; LOW DRUG DOSE; OSTEOARTHRITIS; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STROKE; THROMBOSIS;

ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CYCLOOXYGENASE 2 INHIBITORS; GASTROINTESTINAL TRACT; HUMANS; RISK FACTORS; THROMBOSIS;

EID: 53049091589     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2008.06.004     Document Type: Review

References (60)

1. Smith W.L., DeWitt D.L., and Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69 (2000) 145-182
2. Grosser T., Fries S., and FitzGerald G.A. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 116 1 (2006) 4-15
3. Marcus A.J. Transcellular metabolism of eicosanoids. Prog Hemost Thromb 8 (1986) 127-142
4. Picot D., Loll P.J., and Garavito R.M. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 367 6460 (1994) 243-249
5. Grosser T. The pharmacology of selective inhibition of COX-2. Thromb Haemost 96 4 (2006) 393-400
6. Kargman S., Charleson S., Cartwright M., et al. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 111 2 (1996) 445-454
7. Zimmermann K.C., Sarbia M., Schror K., et al. Constitutive cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa. Mol Pharmacol 54 3 (1998) 536-540
8. Crofford L.J., Wilder R.L., Ristimaki A.P., et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids. J Clin Invest 93 3 (1994) 1095-1101
9. Schonbeck U., Sukhova G.K., Graber P., et al. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 155 4 (1999) 1281-1291
10. Hawkey C.J. Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology 119 2 (2000) 521-535
11. Khanna I.K., Yu Y., Huff R.M., et al. Selective cyclooxygenase-2 inhibitors: heteroaryl modified 1,2-diarylimidazoles are potent, orally active antiinflammatory agents. J Med Chem 43 16 (2000) 3168-3185
12. Tani S., Suzuki T., Kano S., et al. Mechanisms of gastric mucus secretion from cultured rat gastric epithelial cells induced by carbachol, cholecystokinin octapeptide, secretin, and prostaglandin E2. Biol Pharm Bull 25 1 (2002) 14-18
13. Warner T.D., Giuliano F., Vojnovic I., et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A 96 13 (1999) 7563-7568
14. Coruzzi G., Venturi N., and Spaggiari S. Gastrointestinal safety of novel nonsteroidal antiinflammatory drugs: selective COX-2 inhibitors and beyond. Acta Biomed 78 2 (2007) 96-110
15. Seibert K., Masferrer J., Zhang Y., et al. Mediation of inflammation by cyclooxygenase-2. Agents Actions Suppl 46 (1995) 41-50
16. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343 21 (2000) 1520-1528 1522. p. following 1528
17. Silverstein F.E., Faich G., Goldstein J.L., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284 10 (2000) 1247-1255
18. Schnitzer T.J., Burmester G.R., Mysler E., et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364 9435 (2004) 665-674
19. Garavito R.M., and DeWitt D.L. The cyclooxygenase isoforms: structural insights into the conversion of arachidonic acid to prostaglandins. Biochim Biophys Acta 1441 2-3 (1999) 278-287
20. Patrono C., Patrignani P., and Garcia Rodriguez L.A. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest 108 1 (2001) 7-13
21. Cryer B., and Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 104 5 (1998) 413-421
22. FitzGerald G.A., and Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 345 6 (2001) 433-442
23. Capone M.L., Tacconelli S., Di Francesco L., et al. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat 82 1-4 (2007) 85-94
24. Bresalier R.S., Sandler R.S., Quan H., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 11 (2005) 1092-1102
25. Mamdani M., Juurlink D.N., Lee D.S., et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 363 9423 (2004) 1751-1756
26. Pai R., Soreghan B., Szabo I.L., et al. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 8 3 (2002) 289-293
27. Steinbach G., Lynch P.M., Phillips R.K., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342 26 (2000) 1946-1952
28. Bolli R., Shinmura K., Tang X.L., et al. Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res 55 3 (2002) 506-519
29. Rudic R.D., Brinster D., Cheng Y., et al. COX-2-derived prostacyclin modulates vascular remodeling. Circ Res 96 12 (2005) 1240-1247
30. Egan K.M., Wang M., Fries S., et al. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 111 3 (2005) 334-342
31. Francois H., Athirakul K., Howell D., et al. Prostacyclin protects against elevated blood pressure and cardiac fibrosis. Cell Metab 2 3 (2005) 201-207
32. Rabausch K., Bretschneider E., Sarbia M., et al. Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2-derived prostaglandins. Circ Res 96 1 (2005) e1-e6
33. Murata T., Ushikubi F., Matsuoka T., et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388 6643 (1997) 678-682
34. FitzGerald G.A., Brash A.R., Falardeau P., et al. Estimated rate of prostacyclin secretion into the circulation of normal man. J Clin Invest 68 5 (1981) 1272-1276
35. McAdam B.F., Catella-Lawson F., Mardini I.A., et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 96 1 (1999) 272-277
36. Marwali M.R., and Mehta J.L. COX-2 inhibitors and cardiovascular risk. Inferences based on biology and clinical studies. Thromb Haemost 96 4 (2006) 401-406
37. Belton O., Byrne D., Kearney D., et al. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 102 8 (2000) 840-845
38. Cheng Y., Wang M., Yu Y., et al. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest 116 5 (2006) 1391-1399
39. Yamagata K., Andreasson K.I., Kaufmann W.E., et al. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 11 2 (1993) 371-386
40. Breder C.D., Dewitt D., and Kraig R.P. Characterization of inducible cyclooxygenase in rat brain. J Comp Neurol 355 2 (1995) 296-315
41. Whelton A., Schulman G., Wallemark C., et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 160 10 (2000) 1465-1470
42. Aw T.J., Haas S.J., Liew D., et al. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 165 5 (2005) 490-496
43. Whelton A., White W.B., Bello A.E., et al. Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 90 9 (2002) 959-963
44. Sowers J.R., White W.B., Pitt B., et al. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 165 2 (2005) 161-168
45. Solomon D.H., Schneeweiss S., Levin R., et al. Relationship between COX-2 specific inhibitors and hypertension. Hypertension 44 2 (2004) 140-145
46. Graham D.J., Campen D., Hui R., et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365 9458 (2005) 475-481
47. Nissen S.E. Adverse cardiovascular effects of rofecoxib. N Engl J Med 355 2 (2006) 203-204 author reply 203-05
48. Solomon S.D., McMurray J.J., Pfeffer M.A., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 11 (2005) 1071-1080
49. Solomon S.D., Pfeffer M.A., McMurray J.J., et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 114 10 (2006) 1028-1035
50. Bertagnolli M.M., Eagle C.J., Zauber A.G., et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355 9 (2006) 873-884
51. Arber N., Eagle C.J., Spicak J., et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355 9 (2006) 885-895
52. Baron J.A., Sandler R.S., Bresalier R.S., et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 131 6 (2006) 1674-1682
53. Nussmeier N.A., Whelton A.A., Brown M.T., et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352 11 (2005) 1081-1091
54. Solomon S.D., Wittes J., Finn P.V., et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 117 16 (2008) 2104-2113
55. Cannon C.P., Curtis S.P., FitzGerald G.A., et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 368 9549 (2006) 1771-1781
56. Martin B.K., Breitner J.C.S., Evans D., et al. ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials 1 7 (2006) e33
57. Fosbol E.L., Gislason G.H., Jacobsen S., et al. The pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people. Pharmacoepidemiol Drug Saf 17 (Mar 28 2008) 822-833
58. Antman E.M., Bennett J.S., Daugherty A., et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 115 12 (2007) 1634-1642
59. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 43 9 (2000) 1905-1915
60. Catella-Lawson F., Reilly M.P., Kapoor S.C., et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345 25 (2001) 1809-1817